MannKind and Rose Pharma agree to develop inhaled GLP-1 therapy
Go back to MannKind and Rose Pharma agree to develop inhaled GLP-1 therapy| Mannkind Corporation (NASDAQ: MNKD) | Delayed: 3.59 +0.05 (1.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.54 | 52 Week High | $2.51 | |||
| Open | $3.55 | 52 Week Low | $0.41 | |||
| Day High | $3.62 | P/E | N/A | |||
| Day Low | $3.47 | EPS | $-0.64 | |||
| Volume | 979,287 | |||||
